Log In
Print
BCIQ
Print
Print this Print this
 

pidilizumab (CT-011)

  Manage Alerts
Collapse Summary General Information
Company CureTech Ltd.
DescriptionHumanized anti-programmed cell death 1 (PD-1; PDCD1; CD279) mAb
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$335.0M

$5.0M

$330.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today